Lurasidone Pediatric Pharmacokinetics Study

PHASE1CompletedINTERVENTIONAL
Enrollment

105

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

May 31, 2013

Study Completion Date

May 31, 2013

Conditions
SchizophreniaAutism
Interventions
DRUG

Lurasidone

Lurasidone 20, 40,80, 120 or 160 mg/day oral single and multiple does of lurasidone for 12 days

Trial Locations (10)

19139

CRI Worldwide, LLC, Philadelphia

30308

Atlanta Center for Medical Research, Atlanta

33143

Miami Children's Hospital, South Miami

33301

Segal Institute for Clinical Research, Fort Lauderdale

44106

University Hospitals Case Medical Center, Cleveland

45219

University of Cincinnati, Dept. of Psychiatry & Behavioral Neuroscience, Cincinnati

72223

Woodland International Research Group, Inc., Little Rock

72704

Woodland Northwest Research, LLC, Springdale

84058

Aspen Clinical Research, Orem

92562

World Wide Research Centers Inc., Murrieta

All Listed Sponsors
lead

Sumitomo Pharma America, Inc.

INDUSTRY

NCT01620060 - Lurasidone Pediatric Pharmacokinetics Study | Biotech Hunter | Biotech Hunter